Samer Schuman, MD
Gynecologic Oncology · Newburgh, INNPI 1588875009
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,950 of the $2,645 with a category attached, or 73.7%. GSK accounts for 78.8% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2020 at $2,157 and has fallen 97.9% since, to $44 in 2025.
Across 29 payments — averaging $91.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AbbVie$202
- AstraZeneca$100
- Genmab U.S., Inc.$60
- Tesaro, Inc.$49
- Immunogen, Inc.$46
- plus $105 from 4 others
Across 9 payments — averaging $7840.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$71K
What the payments were for
- Consulting fees$1,95074%
- Food & beverage$69526%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 5 | $2,083 |
| AbbVie(2 entities) | 13 | $202 |
| AstraZeneca | 3 | $100 |
| Genmab U.S., Inc. | 1 | $60 |
| Tesaro, Inc. | 1 | $49 |
| Immunogen, Inc. | 2 | $46 |
| Merck | 1 | $43 |
| Medical Device Business Services, Inc. | 1 | $31 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Intuitive Surgical | 1 | $14 |
How this compares
$2,645 in reported general payments places this provider in the 65th percentile of 26 gynecologic oncology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Megestrol Acetate | 17 | $776 |
| Scopolamine | 16 | $232 |
| Ibuprofen | 64 | $197 |
| Anastrozole | 12 | $68 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Newburgh
- Sameer SharmaDyer$27K
- Nonyem OnujioguSouth Bend$23K
- Paul LiuSouth Bend$15K
- Iwona PodzielinskiWarsaw$8K
- Jessica Parker MetterIndianapolis$6K
- Hilary HinshawIndianapolis$5K
- Lisa LandrumIndianapolis$4K
- Scott GoodrichFort Wayne$4K
- James DunlopIndianapolis$3K
- Bogna BrzezinskaFort Wayne$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.